ClinicalTrials.gg
CompletedNCT00254579Updated Jun 7, 2012

Study of CP-675,206 in Refractory Melanoma

A Phase 2 interventional study of CP-675,206 in Refractory Melanoma, sponsored by AstraZeneca. Completed at 65 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-07.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
251
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing tremelimumab in Melanoma — none open to participants now, none under way, none of them phase 3. tremelimumab · Melanoma.

Enrollment
2nd of 12
251 · median 51
Started
2005
the only one that year
Phase 2
5 of 12
none open now
Registered
2nd of 12
by date
Lead sponsor
6 of 12
AstraZeneca

Among the 12 studies testing tremelimumab in Melanoma, this one is the 2nd largest by enrollment, is the only one that started in 2005, is one of 5 in phase 2, and was the 2nd registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

None of the 12 studies testing tremelimumab in Melanoma is open now. The open studies under Melanoma, anywhere →

About tremelimumab

tremelimumab: first FDA approval 2022 (IMJUDO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing tremelimumab in Melanoma as a file.
02

Study summary

CP-675,206 is a fully human monoclonal antibody (mAb). It binds to the CTLA4 molecule, which is expressed on the surface of activated T lymphocytes. CP-675,206 is thought to stimulate patients' immune systems to attack their tumors. CP-675,206 is not expected to have a direct effect on tumor cells. CP-675,206 been shown to induce durable tumor responses in patients with metastatic melanoma in Phase 1 and Phase 2 clinical studies.

03

Conditions studied

  • Refractory Melanoma

Browse trials for

Keywords

  • refractory melanoma
  • malignant melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Surgically incurable Stage III or IV melanoma
  • One prior systemic treatment for melanoma
  • (ECOG) PS = 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Melanoma of ocular origin
  • Received prior vaccine
  • Received prior CTLA4-inhibiting agent
  • History of, or significant risk for, chronic inflammatory or disease
  • Potential requirement for systemic
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
251 participants (actual)

Study arms

  • Experimental
    15 mg/kg CP-675,206

    Drug: CP-675,206

Interventions

06

What researchers measure

Primary outcomes

  1. To assess the anti-tumor efficacy, as determined by objective response rate, of intravenous CP-675,206 administered at a dose of 15 mg/kg every 90 days to patients with relapsed or refractory advanced melanoma

    Time frame: Tumor response is assessed every 2-3 months until disease progression

Secondary outcomes

  1. Safety

    Time frame: At every scheduled visit as specified per protocol for a maximum of 2 years from first dose of drug

  2. Pharmaco Kinetic

    Time frame: At every scheduled visit as specified per protocol for a maximum of 2 years from first dose of drug

  3. Survival

    Time frame: At every scheduled visit as specified per protocol for a maximum of 2 years from first dose of drug

  4. Health-related QoL

    Time frame: At every scheduled visit as specified per protocol for a maximum of 2 years from first dose of drug

07

Study locations

65 sites
  • Research Site
    Scottsdale, Arizona 85260, United States
  • Research Site
    Bentonville, Arkansas 72712, United States
  • Research Site
    Fayetteville, Arkansas 72703, United States
  • Research Site
    Little Rock, Arkansas 72205, United States
  • Research Site
    Los Angeles, California 90095-6970, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Stamford, Connecticut 06902-3628, United States
  • Research Site
    Ocoee, Florida 34761, United States
  • Research Site
    Orlando, Florida 32803, United States
  • Research Site
    Orlando, Florida 32804, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Indianapolis, Indiana 46202, United States
  • Research Site
    Indianapolis, Indiana 46237, United States
  • Research Site
    Indianapolis, Indiana 46260, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    Baltimore, Maryland 21237-3998, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Ann Arbor, Michigan 48109-0946, United States
  • Research Site
    Buffalo, New York 14263, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    Chapel Hill, North Carolina 27599-7600, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Pfizer Investigational Site
    Columbus, Ohio 43210, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Bethlehem, Pennsylvania 18015, United States
  • Research Site
    Pittsburgh, Pennsylvania 15232, United States
  • Research Site
    Nashville, Tennessee 37232-6307, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    Salt Lake City, Utah 84112, United States
  • Research Site
    Federal Way, Washington 98003, United States
  • Research Site
    Lakewood, Washington 98499, United States
  • Research Site
    Seattle, Washington 98104, United States
  • Research Site
    Seattle, Washington 98122, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Madison, Wisconsin 53792, United States
  • Research Site
    Ciudad de Buenos Aires, Buenos Aires C1280AEA, Argentina
  • Research Site
    Waratah, New South Wales 2298, Australia
  • Research Site
    Westmead, New South Wales 2145, Australia
  • Research Site
    Woolloongabba, Queensland 4102, Australia
  • Research Site
    East Melbourne, Victoria 3002, Australia
  • Research Site
    Nedlands, Western Australia 6009, Australia
  • Research Site
    Hamilton, Ontario L8V 5C2, Canada
  • Research Site
    Lille, Cedex 59037, France
  • Research Site
    Paris Cedex 13, 75651, France
  • Research Site
    Villejuif, 94805, France
  • Research Site
    Berlin, 10117, Germany
  • Research Site
    Frankfurt, 60488, Germany
  • Research Site
    Kiel, 24105, Germany
  • Research Site
    Tuebingen, 72076, Germany
  • Research Site
    Meldola, FC, 47014, Italy
  • Research Site
    Milano, 20132, Italy
  • Research Site
    Milano, 20133, Italy
  • Research Site
    Milano, 20141, Italy
  • Research Site
    Pamplona, Navarra 31008, Spain
  • Research Site
    Barcelona, 08036, Spain
  • Research Site
    Madrid, 28046, Spain
  • Research Site
    Zaragoza, 50009, Spain
  • Research Site
    Truro, Cornwall TR1 3LJ, United Kingdom
  • Research Site
    Northwood, Middlesex HA6 2RN, United Kingdom
  • Research Site
    Sutton, Surrey SM2 5PT, United Kingdom
  • Research Site
    Newcastle upon Tyne, Tyne and Wear NE4 6BE, United Kingdom
  • Research Site
    London, SW3 6JJ, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom
  • Research Site
    Newcastle Upon Tyne, NE7 7DN, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2005
First posted
Nov 16, 2005
Start
Dec 2005
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Results delay requested
May 9, 2009
Last update
Jun 7, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00254579
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 16, 2005
Start date
Dec 2005
Primary completion
Dec 2009
Completion
Dec 2009
Last update
Jun 7, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tremelimumab

Start the discussion